SCHEMBL2905653

SCHEMBL2905653

CN(C)c1ccc(C=[C]F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.52
CYP2A13 Q16696 1/20 0.52
APP P05067 4/20 0.52
ALDH1A1 P00352 8/20 0.50
ALOX15 P16050 4/20 0.50
HSD17B10 Q99714 2/20 0.50
TSHR P16473 2/20 0.50
KDM4E B2RXH2 3/20 0.48
HSD17B3 P37058 1/20 0.48
RELA Q04206 1/20 0.48
MAPT P10636 6/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.45
CASP1 P29466 2/20 0.45
HBB P68871 2/20 0.45
THRB P10828 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TP53 P04637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906435 0.79 CYP2A6 (0.54) CYP2A6CYP2A13APPALDH1A1ALOX15
SCHEMBL12159981 0.77 CYP2A6 (0.52) CYP2A6CYP2A13APPALDH1A1ALOX15
SCHEMBL28865533 0.77 CYP2A6 (0.58) CYP2A6CYP2A13APPALDH1A1ALOX15
SCHEMBL4363036 0.76 CYP2A6 (0.50) CYP2A6CYP2A13APPALDH1A1ALOX15
SCHEMBL11045260 0.74 CYP2A6 (0.48) CYP2A6CYP2A13APPALDH1A1ALOX15
SCHEMBL9170470 0.74 APP (0.52) CYP2A6CYP2A13APPALDH1A1ALOX15
SCHEMBL3126253 0.73 NFE2L2 (0.46) CYP2A6ALDH1A1KDM4ERELAMAPT
SCHEMBL3131905 0.73 NFE2L2 (0.46) CYP2A6ALDH1A1KDM4ERELAMAPT
SCHEMBL3126258 0.73 NFE2L2 (0.46) CYP2A6ALDH1A1KDM4ERELAMAPT
SCHEMBL13467434 0.72 RELA (0.81) CYP2A6CYP2A13APPALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2759543-B1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORP (JP) 2017-07-19 EP disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
EP-2725017-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2016-06-29 EP disclosed
EP-2669277-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-07-01 EP disclosed
EP-2684886-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-06-03 EP disclosed
EP-2669278-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-05-27 EP disclosed
US-8916071-B2 Chromene compound and curable composition TOKUYAMA CORPORATION (JP) 2014-12-23 US disclosed
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2014-08-14 US disclosed
EP-2759543-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION Tokuyama Corporation (JP) 2014-07-30 EP disclosed
US-8778236-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-07-15 US disclosed
EP-1655294-A2 Chromene compound Tokuyama Corporation (JP) 2006-05-10 EP disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
EP-1054010-B1 Chromene compound TOKUYAMA CORP (JP) 2002-07-24 EP disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
US-6340765-B1 PHOTOCHROMIC DYES AND DEVELOPMENT TOKUYAMA CORPORATION (JP) 2002-01-22 US disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed
EP-1054010-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 CYP2A6 2241/4885CYP2A13 1014/4885APP 3013/4885
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION CRY2, CRY1, CDYL CYP2A6 798/4885CYP2A13 904/4885APP 3110/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 CYP2A6 2342/4885CYP2A13 935/4885APP 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.